Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Performance

Shares of EVGN stock opened at $1.33 on Friday. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.00. The firm has a market capitalization of $7.14 million, a PE ratio of -0.30 and a beta of 1.29. The stock’s 50-day simple moving average is $1.59 and its 200-day simple moving average is $2.09.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.